Maze Therapeutics, INC Schedule 13G passive stakes

Paradigm BioCapital entities and Senai Asefaw have filed an amendment to their Schedule 13G, reporting no change in beneficial ownership of Maze Therapeutics common stock as of June 30, 2026.

Janus Henderson Group plc has reported beneficial ownership of 5.8% of Maze Therapeutics, Inc. common stock as of March 31, 2026.

Paradigm BioCapital Advisors LP and related entities have reported a 6.1% beneficial ownership stake in Maze Therapeutics, Inc. common stock.

Frazier Life Sciences Public Fund and affiliated entities disclose a combined 9.0% beneficial ownership in Maze Therapeutics, Inc. common stock.

Third Rock Ventures entities have reported a combined beneficial ownership of 11.3% in Maze Therapeutics, Inc. common stock.

Alphabet Inc. and its venture capital arm, GV, have disclosed a 2.9% beneficial ownership stake in Maze Therapeutics, Inc. through a Schedule 13G amendment.

Foresite Capital entities and James Tananbaum report a combined 1.4% beneficial ownership in Maze Therapeutics, Inc. common stock.

Janus Henderson Group plc has increased its beneficial ownership in Maze Therapeutics, Inc. to 7.3% of common stock, holding over 3.2 million shares.

Matrix Capital Management Company, LP and David E. Goel have reported a 3.5% beneficial ownership stake in Maze Therapeutics, Inc., holding 1,653,684 shares of common stock.

Frazier Life Sciences funds disclose updated beneficial ownership in Maze Therapeutics, clarifying individual attributions.

Janus Henderson Group plc has reported a 6.0% beneficial ownership stake in Maze Therapeutics, Inc., holding 2,625,089 shares of common stock.

Deep Track Capital and affiliates report a 9.02% beneficial ownership stake in Maze Therapeutics Inc., holding 3,948,910 shares.

ARCH Venture Fund X and related entities, along with their key members, have disclosed a collective beneficial ownership of 9.4% in Maze Therapeutics, Inc., totaling 4,120,053 shares of common stock.

Matrix Capital Management Company, LP and David E. Goel have jointly disclosed a passive beneficial ownership of 5.7% in Maze Therapeutics, Inc., totaling 2,486,184 common shares.

Janus Henderson Group plc has filed a Schedule 13G, reporting a beneficial ownership of 5.7% of Maze Therapeutics, Inc.'s common stock as of March 31, 2025.

Alphabet Inc. and its affiliated investment entities, including GV, have disclosed a passive beneficial ownership of 5.5% of Maze Therapeutics, Inc.'s common stock as of March 31, 2025.

Third Rock Ventures entities have filed a Schedule 13G, revealing beneficial ownership of 16.1% of Maze Therapeutics, Inc.'s common stock as of January 31, 2025.

An amended Schedule 13G filing reveals that Frazier Life Sciences funds and their managing principals collectively hold substantial beneficial ownership in Maze Therapeutics, Inc., with two individuals exceeding the 10% threshold.

Frazier Life Sciences and affiliated funds have filed an amended Schedule 13G, disclosing their updated passive beneficial ownership in Maze Therapeutics, Inc., with key individuals holding up to 9.4% of the common stock.

Frazier Life Sciences and its affiliated funds, along with key individuals, have disclosed beneficial ownership of up to 7.3% of Maze Therapeutics, Inc.'s common stock following the company's recent initial public offering.

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has reported a collective beneficial ownership of 6.91% in Maze Therapeutics Inc.

Foresite Capital entities and James Tananbaum have filed a Schedule 13G, reporting a combined beneficial ownership of 5.6% of Maze Therapeutics, Inc.'s common stock as of January 31, 2025.

Foresite Capital entities and James Tananbaum have filed a Schedule 13G, revealing a combined beneficial ownership of 5.6% of Maze Therapeutics, Inc.'s common stock as of January 31, 2025.